LENSAR, Inc. (LNSR) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite a decline in Q4 revenue, the company showcased strong recurring revenue and procedure volume growth, indicating a solid customer base and utilization. However, international sales were negatively impacted by distributor uncertainty, and gross margins slightly declined. The Q&A revealed challenges in rebuilding international momentum and an expected increase in operating expenses. Overall, the mixed signals from financial performance and market strategy suggest a neutral sentiment, with potential for improvement if international sales recover and cost management is effective.
Key Financial Performance
Revenue Total revenue for Q4 2025 was $16 million, representing a 4% decline year-over-year, primarily due to lower system sales. Full year 2025 revenue increased by 9% compared to 2024. The decline in Q4 revenue was attributed to distributor uncertainty regarding the acquisition.
Recurring Revenue Recurring revenue grew 17% in Q4 2025 to $12.7 million, annualizing to over $50 million. Full year 2025 recurring revenue was $46.3 million, up 15% compared to $40.1 million in 2024. This growth reflects the expansion of the installed base and increased system utilization.
Procedure Volume Fourth quarter 2025 procedure volume increased approximately 20% year-over-year. Full year 2025 procedure volume grew 22%, surpassing 206,000 globally. This growth was driven by the expansion of the ALLY installed base and increased utilization.
Installed Base The installed base of ALLY systems grew to just over 200 by the end of 2025, up 48% year-over-year. The total combined installed base of ALLY and LLS systems grew to approximately 435, an increase of 13%. This growth was attributed to increased placements and market share gains.
Gross Margin Gross margin for Q4 2025 was $6.9 million, representing a gross margin percentage of 43%, compared to 42% in Q4 2024. Full year 2025 gross margin was 46%, down from 48% in 2024. The decline was due to inflationary cost increases, production costs, and tariffs, which were not passed on to customers.
Adjusted EBITDA Adjusted EBITDA for Q4 2025 was $595,000, indicating positive operating cash flow. Full year 2025 also maintained positive adjusted EBITDA despite the challenges posed by the acquisition process.
System Sales U.S. ALLY sales in Q4 2025 were 12 systems, up from 11 in Q4 2024. However, only 1 ALLY system was sold outside the U.S. in Q4 2025, compared to 10 in Q4 2024. The decline in international sales was attributed to distributor uncertainty during the acquisition process.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ALLY Robotic Laser Cataract System: Recognized as the best next-generation technology for laser-assisted cataract surgery, featuring advanced ergonomics, efficiencies, imaging, and automated treatment planning with a dual modality laser. Employs machine learning for optimized treatment outcomes.
Market Share Growth: Increased U.S. market share from 14% to 23.4% by the end of 2025, gaining 9.5% in 3.5 years. Growth attributed to replacing first-generation lasers, increasing procedure volumes, and attracting Femto-naive surgeons.
International Expansion: ALLY launched internationally after receiving European certification in 2024. Initial success was slowed due to acquisition uncertainty but is expected to regain momentum post-termination of the merger.
Procedure Volume Growth: Achieved 20% year-over-year growth in procedure volume for Q4 2025 and 22% growth for the full year, surpassing 206,000 globally.
Recurring Revenue: Increased recurring revenue by 15% in 2025, reaching $46.3 million, driven by expanded installed base and higher system utilization.
Post-Acquisition Strategy: Reengaging as an independent company after the terminated acquisition with Alcon. Focused on growth, stakeholder relationships, and operational cadence.
Financial Adjustments: Received $10 million transaction deposit post-merger termination. Adjusted liabilities and deferred payments to stabilize financial position.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: The Federal Trade Commission (FTC) blocked the merger between LENSAR and Alcon, leading to the termination of the acquisition agreement. This regulatory challenge caused significant financial and operational disruptions, including increased SG&A expenses and halted international distributor activities.
Market Uncertainty: The acquisition process created uncertainty among U.S. customers, potential customers, and international distributors, delaying decision-making and negatively impacting sales and operations.
International Business Disruption: The uncertainty surrounding the acquisition caused a slowdown in international business expansion, with distributors halting activities and system sales outside the U.S. declining significantly.
Inflationary Costs and Tariffs: Inflationary cost increases and tariffs impacted gross margins, with the company absorbing tariff costs instead of passing them on to customers.
Competitive Pressures: Competitors have deeper financial, human, and operational resources, as well as the ability to bundle more products, posing a challenge to LENSAR's market share growth.
Operational Transition Risks: The company faces challenges in transitioning back to independent operations after the terminated acquisition, including reestablishing distributor relationships and regaining lost momentum in international markets.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects a gradual return to historical operating performance over the next several quarters of 2026. Long-term growth metrics indicate a positive trajectory, with procedure volumes up 50% compared to 2023.
Market Share Expansion: LENSAR aims to continue gaining market share, building on the 9.5% increase achieved over the past 3.5 years. The company plans to focus on replacing competitive systems and expanding the market for robotic laser cataract procedures.
International Business Growth: The company anticipates significant system growth in international markets over time, following the termination of the merger. Distributors are expected to reengage, although the recovery of momentum may take time.
Recurring Revenue: Recurring revenue is expected to grow through increased system placements and higher utilization of the 200 ALLY systems currently in the field. This revenue stream is stable, predictable, and carries higher margins.
Gross Margin Improvement: Gross margin percentage is forecasted to increase to a range of 46% to 49% for fiscal 2026, depending on the success of system sales.
Cash Flow and Financial Stability: The company plans to enhance cash flow by increasing system sales, particularly outside the United States. The combination of cash on hand and extended payment terms for acquisition costs provides financial flexibility.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What can you tell us about the distributor commentary and how it translates to OUS system revenues?
A:Nicholas Curtis explained that the business outside the U.S. is different, with some regions relying on tenders that take time to reengage. Distributors were hesitant due to uncertainty, and there has been no activity for the last 9 months. It will take several quarters to rebuild momentum, with no backlog as distributors planned for life without LENSAR. The company expects to regain momentum by the last quarter of 2024.
Q:How should we think about placements going forward, particularly the mix of lease-based versus capital sales?
A:Nicholas Curtis stated that outside the U.S., revenue is recognized upon system sale, while in the U.S., revenue recognition occurs after installation, training, and acceptance. Historically, about 50-55% of systems in the U.S. were sold versus placed, but this percentage is expected to drop as competition drives price competitiveness. The company anticipates a shift towards more lease-based placements in the U.S.
Q:Can you clarify the 10% increase in cash OpEx for 2026?
A:Thomas Staab confirmed that the 10% increase is based on cash-based operating expenses, excluding amortization and stock-based compensation. This would result in operating expenses of approximately $38-39 million for 2026.
Q:Can you comment on U.S. procedure growth and the recurring revenue outlook for 2026?
A:Nicholas Curtis highlighted that recurring revenue reached $46 million in 2025, with 79% of revenue in Q4 being recurring. The company expects continued growth in procedures, with ALLY units in the U.S. averaging 600 procedures per year. New customers, particularly those new to femtosecond laser technology, take longer to ramp up but represent significant growth potential. Astigmatism management is a key driver, with over 65% of procedures involving it.
Q:Will operating expenses accelerate beyond the 10% increase in 2026?
A:Thomas Staab acknowledged that expenses decreased during the acquisition process and will increase primarily for commercial activities in 2026. As distributors come online and cash flow improves, the company plans to ramp up commercial activities significantly in 2027.
Q:Does your strategy for OUS efforts change post-merger termination?
A:Nicholas Curtis indicated that the company is exploring new opportunities in markets like Australia, New Zealand, and parts of Latin America. Southeast Asia and Europe are expected to see growth, with a focus on replacing older competitive systems. South Korea remains a challenging market due to reimbursement issues.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to Ryan Zimmerman's question about whether the 10% increase in operating expenses is sufficient for 2027 and beyond. While they acknowledged the need for increased expenses in the future, the response lacked specific details or a clear plan for long-term expense growth.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ALLY LENSAR
ALLY Robotic
ALLY launch
ALLY market
ALLY system
Cataract System
LENSAR ALLY
LENSAR surgeon
Laser Cataract
Robotic Laser
announcement
average laser
cataract procedure
confidence
decision
distribution
distributor termination
end
evidence
forward
gain share
generation laser
laser ALLY
machine learning
market laser
merger
month
point
procedure average
resource
return
support
surgeon practice
termination acquisition
trajectory
transaction
treatment planning
value
LNSR Transcript
LENSAR, Inc. (LNSR) Q4 2025 Earnings Call Transcript
Unknown3-31
Despite a decline in Q4 revenue, the company showcased strong recurring revenue and procedure volume growth, indicating a solid customer base and utilization. However, international sales were negatively impacted by distributor uncertainty, and gross margins slightly declined. The Q&A revealed challenges in rebuilding international momentum and an expected increase in operating expenses. Overall, the mixed signals from financial performance and market strategy suggest a neutral sentiment, with potential for improvement if international sales recover and cost management is effective.
LENSAR, Inc. (NASDAQ:LNSR) Q4 2024 Earnings Call Transcript
Unknown3-3
The earnings call showed mixed signals. While there was significant revenue growth and positive adjusted EBITDA, the net loss was substantial due to noncash charges. The lack of shareholder return plans and competitive pressures are concerning. However, strong system placements, market expansion, and positive recurring revenue growth offset these issues. The Q&A revealed no immediate threats from competitors but highlighted potential strategic shifts. Overall, the financial results and strategic outlook suggest a neutral sentiment, with no strong catalysts for significant short-term stock price movement.
LENSAR, Inc. (LNSR) Q4 2024 Earnings Call Transcript
Unknown2-28
The earnings call shows mixed signals: strong revenue growth and positive adjusted EBITDA are offset by financial losses and competitive pressures. The Q&A highlights strategic growth in new markets but lacks concrete guidance, leaving uncertainties. The absence of a shareholder return plan and regulatory risks further balance the positives. Thus, a neutral stock price movement is expected.
LENSAR, Inc. (LNSR) Q3 2024 Earnings Call Transcript
Unknown11-9
The earnings call summary shows strong revenue growth and market expansion, but challenges include declining gross margins, increased expenses, and a net loss. The Q&A section reveals uncertainties in future guidance and revenue recognition. While there are positive aspects like increased market share and cash position, risks like regulatory delays and competitive pressures temper the outlook. The absence of a shareholder return plan further contributes to a neutral sentiment. Without a market cap, the stock's reaction is uncertain, suggesting a neutral prediction for the next two weeks.
LNSR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
